Low-Dose Colchicine Approved for CVD: Now What?

The FDA has given the new low dose of colchicine a broad indication for use in atherosclerotic cardiovascular disease, but how will the drug actually be used in clinical practice?

Related Keywords

Boston ,Massachusetts ,United States ,Canada ,Ohio ,Jean Claude Tardif ,Steve Nissen ,Agepha Pharma ,Michael Joseph Blaha ,Paul Ridker ,Clinical Research ,Drug Administration ,Ciccarone Center ,Research Centre ,Heart Institute ,Cardiovascular Disease ,Johns Hopkins Hospital ,Cardiovascular Disease Prevention ,Second Pillar ,Cleveland Clinic ,Cv ,Ardiovascular ,Lipids ,Ipid Management ,Statin ,Lipid Lowering Drugs ,Rug Lipid Lowering ,Atherosclerotic Heart Disease ,Therosclerotic Cardiovascular Disease ,Oronary Heart Disease ,Schemic Heart Disease ,Heart Failure ,Vd Cardiovascular Disease ,Patient Safety ,Atherosclerosis ,Coronary Atherosclerosis ,Drug Interactions ,Infarct ,Infarction ,Myocardial Infarction ,Bac ,